Go back to the Europarl portal

Choisissez la langue de votre document :

  • bg - български
  • es - español
  • cs - čeština
  • da - dansk
  • de - Deutsch
  • et - eesti keel
  • el - ελληνικά
  • en - English (Selected)
  • fr - français
  • ga - Gaeilge
  • hr - hrvatski
  • it - italiano
  • lv - latviešu valoda
  • lt - lietuvių kalba
  • hu - magyar
  • mt - Malti
  • nl - Nederlands
  • pl - polski
  • pt - português
  • ro - română
  • sk - slovenčina
  • sl - slovenščina
  • fi - suomi
  • sv - svenska
Parliamentary questions
PDF 38kWORD 16k
11 June 2021
E-001917/2021(ASW)
Answer given by Ms Kyriakides
on behalf of the European Commission
Question reference: E-001917/2021

The Commission has been negotiating intensely to build a diversified portfolio of vaccines for EU citizens at fair prices. Contracts have been concluded with six promising vaccine developers, securing a portfolio of more than 4.4 billion doses and negotiations are underway for additional doses.

The Novavax vaccine is a protein subunit product already in phase 3 clinical trial stage. The Commission, with the support of EU Member States, is interested in this vaccine.

On 17 December 2020, the Commission concluded exploratory talks(1) with the Novavax, with a view to purchasing its potential vaccine against COVID-19. The envisaged contract would provide for the possibility of all EU Member States to initially purchase 100 million doses, followed up by 100 million additional ones. The negotiations on the contractual terms with the company are currently ongoing.

The Commission is committed to transparency and accountability and is providing regular updates on the COVID-19 vaccine strategy to the citizens via a dedicated website(2). At the same time, the Commission has engaged in consultations with vaccines manufacturers concerning the possibility to disclose both advance purchase agreements and purchase agreements concluded for COVID-19 vaccines. The redacted versions of the agreements with Janssen Pharmaceutica NV(3), CureVac AG(4), Sanofi Pasteur SA & GlaxoSmithKline Biologicals SA(5), AstraZeneca(6), BioNTech/Pfizer(7)(8) and Moderna(9) are already published on the Commission website and the discussions with other manufacturers are ongoing.

(1)https://ec.europa.eu/commission/presscorner/detail/en/ip_20_2305
(2)https://ec.europa.eu/info/live-work-travel-eu/coronavirus-response/public-health/eu-vaccines-strategy_en
(3)https://ec.europa.eu/info/sites/default/files/jj_apa_202005071550.pdf
(4)https://ec.europa.eu/info/files/curevac-redacted-advance-purchase-agreement_en
(5)https://ec.europa.eu/info/files/sanofi-gsk-redacted-advance-purchase-agreement_en
(6)https://ec.europa.eu/info/sites/info/files/apa_astrazeneca.pdf
(7)https://ec.europa.eu/info/sites/info/files/redacted_advance_purchase_agreement_biontech-pfizer_0.pdf
(8)https://ec.europa.eu/info/sites/info/files/redacted_purchase_agreement_biontech-pfizer_0.pdf
(9)https://ec.europa.eu/info/sites/info/files/redacted_advance_purchase_agreement_moderna_0.pdf
Last updated: 11 June 2021Legal notice - Privacy policy